CINECA IRIS Institutional Research Information System

MENCONI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.016
AS - Asia 1.463
EU - Europa 1.169
SA - Sud America 192
AF - Africa 90
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.942
SG - Singapore 511
CN - Cina 366
SE - Svezia 283
IT - Italia 254
HK - Hong Kong 233
DE - Germania 168
BR - Brasile 153
VN - Vietnam 132
FR - Francia 96
GB - Regno Unito 80
BG - Bulgaria 75
CA - Canada 45
FI - Finlandia 44
IN - India 42
RU - Federazione Russa 39
AT - Austria 38
CI - Costa d'Avorio 38
TR - Turchia 38
JP - Giappone 29
SN - Senegal 22
BD - Bangladesh 19
IQ - Iraq 18
UA - Ucraina 18
NL - Olanda 16
MX - Messico 12
SA - Arabia Saudita 12
ZA - Sudafrica 12
AR - Argentina 10
PL - Polonia 10
PK - Pakistan 9
VE - Venezuela 9
ES - Italia 8
IE - Irlanda 8
BE - Belgio 7
PH - Filippine 7
ID - Indonesia 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
LT - Lituania 5
PS - Palestinian Territory 5
AU - Australia 4
CL - Cile 4
CO - Colombia 4
UZ - Uzbekistan 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EC - Ecuador 3
EG - Egitto 3
LB - Libano 3
PA - Panama 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
BS - Bahamas 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KR - Corea 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SR - Suriname 1
TW - Taiwan 1
Totale 5.935
Salva come PNG Salva come JPEG
Città #
Dallas 353
Ashburn 344
Woodbridge 262
Singapore 245
Hong Kong 229
Fairfield 219
San Jose 219
Houston 167
Santa Clara 148
Chandler 139
Ann Arbor 107
Seattle 92
Beijing 82
Sofia 75
Shanghai 72
Wilmington 72
New York 67
Serra 66
Los Angeles 65
Cambridge 61
Munich 59
Florence 41
Abidjan 38
Boardman 35
London 35
Ho Chi Minh City 34
Vienna 34
Ottawa 33
Princeton 32
Lawrence 27
Bremen 26
Frankfurt am Main 26
Hanoi 24
Lauterbourg 24
Medford 24
Tokyo 24
Turku 23
Dakar 22
Istanbul 19
Pisa 19
Des Moines 18
Dong Ket 18
Marseille 17
Redondo Beach 17
Chicago 15
Dearborn 15
Nanjing 14
Ogden 14
Orem 14
Lancaster 13
Atlanta 12
Buffalo 11
Düsseldorf 11
Rome 11
Chennai 10
Izmir 10
Baghdad 9
Denver 9
Helsinki 9
Johannesburg 9
Lucca 9
São Paulo 9
Warsaw 9
Nanchang 8
San Diego 8
Brussels 7
Fuzhou 7
Kunming 7
Manchester 7
Riyadh 7
Baltimore 6
Changsha 6
Columbus 6
Dhaka 6
Dublin 6
Guangzhou 6
Montreal 6
Paris 6
Poplar 6
Tianjin 6
Gaza 5
Hebei 5
Houten 5
Jacksonville 5
Jinan 5
Milan 5
Portsmouth 5
Rio de Janeiro 5
Stockholm 5
Aosta 4
Baku 4
Belo Horizonte 4
Cagliari 4
Da Nang 4
Haiphong 4
Jüchen 4
Kent 4
Mexico City 4
Naples 4
Nuremberg 4
Totale 4.166
Salva come PNG Salva come JPEG
Nome #
Natural history of graves’ orbitopathy after treatment 265
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? 222
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 217
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 217
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 212
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 189
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) 187
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 182
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 181
Optic neuropathy in 2 thyroidectomized patients with moderate to severe Graves’ ophthalmopathy following L-thyroxine withdrawal prior to radioiodine treatment for thyroid carcinoma 178
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 172
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 171
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 153
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study 151
PREGO ( presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 148
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial 147
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 141
Hypothyroidism Due to L-T4 Withdrawal Can Precipitate Optic Neuropathy in Patients with Moderate to Severe Graves' Ophthalmopathy: Report on Two Cases 138
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 133
Selenium in Graves Hyperthyroidism and Orbitopathy 131
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy 125
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus 123
null 121
Sirolimus as a second-line treatment for Graves' orbitopathy 108
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy 108
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy 105
null 100
IgG4 serum levels in Graves' orbitopathy 97
null 95
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 94
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort Study 94
null 93
null 91
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 90
null 88
Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 87
Role of genetics and epigenetics in Graves’ orbitopathy 85
Graves disease: latest understanding of pathogenesis and treatment options 81
Absence of a relationship between vitamin D and Graves’ orbitopathy 77
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 71
Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 70
null 70
An update on the medical treatment of Graves' hyperthyroidism. 70
Diagnosis and classification of Graves' disease 67
null 65
Role of genetic and non-genetic factors in the etiology of Graves' disease 63
null 57
Absence of a relationship between vitamin D and Graves’ orbitopathy 54
Total thyroid ablation in Graves' orbitopathy 49
Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum 4
null 3
null 1
null 1
Totale 6.042
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 14 27
2021/2022446 1 6 5 41 88 49 3 18 65 68 3 99
2022/2023580 66 119 49 42 42 48 5 41 118 0 48 2
2023/2024218 7 10 24 8 26 58 4 16 3 3 34 25
2024/20251.348 10 33 16 56 119 137 94 47 130 174 168 364
2025/20261.934 164 243 333 166 216 136 275 99 93 184 25 0
Totale 6.042